Ueda Taeko
   Department   School of Medicine  Obstetrics and Gynecology, Clinical Medical Sciences
Article types journal article
Language English
Peer review Non peer reviewed
Title The Safety of Pegylated Liposomal Doxorubicin Plus Irinotecan in Recurrent Ovarian Cancer Patients: A Phase I Trial.
Journal Formal name:Anticancer research
Abbreviation:Anticancer Res
ISSN code:17917530/02507005
Domestic / ForeginForegin
Publisher International Institute of Anticancer Research
Volume, Issue, Page 35(8),4521-4526頁
Author and coauthor Miyahara Daisuke, Ueda Taeko, Katsuda Takahiro, Maehara Miyako, Fukagawa Satoshi, Miyata Kohei, Nam Sung Ouk, Kondo Haruhiko, Miyamoto Shingo
Publication date 2015/08
Summary AIM:The study was designed to evaluate the safety of combined chemotherapy with pegylated liposomal doxorubicin (PLD) and irinotecan (CPT-11) in patients with recurrent ovarian cancer.PATIENTS AND METHODS:Six patients with platinum-resistant and taxane-pretreated ovarian cancer were enrolled in the study based on the traditional 3-plus-3 design. PLD was administered intravenously on day 1 and CPT-11 on days 1 and 8 of each 28-day course. Initial doses were 30 mg/m(2) PLD and 50 mg/m(2) CPT-11.RESULTS:Hematotoxicity was the principal toxicity (1 patient developed grade 3 neutropenia and 2 developed grade 3 leukocytopenia); hand-foot syndrome was not observed. Furthermore, 1 patient achieved complete response, whereas 2 patients achieved partial response.CONCLUSION:The combined PLD and CPT-11 regimen was well-tolerated indicating its potential clinical benefit for ovarian cancer patients.
PMID 26168496